Search
forLearn
5 / 23 resultslearn Platelet-Derived Growth Factor Beta Polypeptide
learn sh-Polypeptide-7
learn Stem Cell Factor
learn Epidermal Growth Factor
Research
5 / 1000+ results
research FCE 28260, A New 5α-Reductase Inhibitor: In Vitro and In Vivo Effects
FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.
research AKR1D1 Regulates Glucocorticoid Availability and Glucocorticoid Receptor Activation in Human Hepatoma Cells
AKR1D1 controls glucocorticoid levels and receptor activity in liver cells.
research Trends in the Development of New Drugs for the Treatment of Benign Prostatic Hyperplasia
New treatments for enlarged prostate are being developed to be more effective and have fewer side effects.
research Synthesis of Phenanthridin-3-One Derivatives: Non-Steroidal Inhibitors of Steroid 5-Alpha-Reductase
New chemicals were made that can block an enzyme linked to hair loss, prostate growth, and acne.
research Selective Non-Steroidal Inhibitors of 5α-Reductase Type 1
Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.
Community Join
5 / 1000+ results
community FCE 28260: A Forgotten 5α-Reductase Inhibitor
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
community UPDATE: The theory that explains everything. Please help me make this big!
Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.
community SCUBE3 is going to save us!!! This is the news we've all been waiting for...
User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.
community The theory that explains everything. Please help me make this big!
The post and conversation are about the role of the enzyme 3alpha-hydroxysteroid reductase in hair loss and the potential of compounds like procyanidin B2 and sulforaphane to boost its activity for hair regrowth. Further research is needed to develop effective treatments based on this theory.
community Verteporfin Phase 1 Human Clinical Trial In The Works
Verteporfin human clinical trials for hair loss may start in 2025. Additional resources and presentations are available for more information.